The U.S. Department of Justice (DOJ) is moving forward with plans to merge the Drug Enforcement Administration (DEA) and the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), according to sources familiar with the matter. The consolidation, which would mark the DOJ's most significant restructuring since 9/11, is expected to be proposed as part of the White House's full fiscal year 2026 budget.
Officials from both agencies were briefed on the plan during a Thursday meeting, with a tentative timeline targeting October for the merger. While the DOJ aims to streamline operations and budgets, the proposal still requires congressional approval. Current federal law prohibits the transfer of ATF funds to other departments, presenting a potential legal hurdle.
The idea first surfaced in March in a memo from Deputy Attorney General Todd Blanche, who suggested multiple structural changes across the DOJ. While several of those changes, such as the breakup of the Tax Division and Consumer Protection Branch, have already been approved, the DEA-ATF merger remains under discussion.
Combining the two agencies would create significant logistical challenges, particularly in merging their distinct missions. The DEA oversees drug enforcement and the regulation of pharmacies and drug manufacturers, while the ATF focuses on firearms regulation and explosives control.
A recent internal DOJ email confirmed that many of Blanche’s reorganization initiatives are advancing. However, concerns remain within both agencies that merging budgets won’t sufficiently cover rising operational costs. The White House’s initial “skinny” FY2026 budget already outlined substantial cuts to the DOJ, including reductions for the FBI, DEA, and ATF.
As the DOJ pushes forward, the proposed merger could reshape federal law enforcement and redefine how the U.S. tackles drug and firearm-related crimes.


Netanyahu to Meet Trump in Washington as Iran Nuclear Talks Intensify
Trump Signs “America First Arms Transfer Strategy” to Prioritize U.S. Weapons Sales
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants
Federal Judge Restores Funding for Gateway Rail Tunnel Project
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions
Jack Lang Resigns as Head of Arab World Institute Amid Epstein Controversy
Trump Orders DHS to Avoid Protests in Democratic Cities Unless Federal Assets Are Threatened
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
US Pushes Ukraine-Russia Peace Talks Before Summer Amid Escalating Attacks
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Ohio Man Indicted for Alleged Threat Against Vice President JD Vance, Faces Additional Federal Charges
Paul Atkins Emphasizes Global Regulatory Cooperation at Fintech Conference 



